stockportfolio.pro
Ocugen, Inc. (OCGN)
Healthcare · Biotechnology · NasdaqCM
Ocugen, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $43,000 | $0 | $2.49M | $6.04M | $4.05M | $4.41M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-16.21M | $-26.41M | $-18.22M | $-20.24M | $-21.82M | $-58.37M | $-86.80M | $-63.08M | $-54.05M | $-67.85M |
| Net margin | — | — | — | — | -50748.8% | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
Source: Ocugen, Inc. SEC filings (10-K). 12 years of history available in the interactive view.
Explore 12 years of Ocugen, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track OCGN in your portfolio →
Ocugen, Inc. financial history by metric
About Ocugen, Inc.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Ocugen, Inc. — frequently asked questions
What is Ocugen, Inc.'s revenue?
Ocugen, Inc. (OCGN) reported revenue of $4.41M for fiscal year 2025, up 8.8% from the prior year, according to its SEC filings.
Is Ocugen, Inc. profitable?
No — OCGN reported a net loss of $-67.85M in fiscal 2025.
What is OCGN's P/E ratio?
Ocugen, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Ocugen, Inc. growing?
OCGN's revenue grew at roughly 152.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Ocugen, Inc. have?
As of fiscal year 2025, OCGN carried roughly $28.79M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Ocugen, Inc.'s market cap?
Ocugen, Inc. (OCGN) has a market capitalization of about $419.70M, based on the latest data in our nightly-refreshed cache.
When does Ocugen, Inc.'s fiscal year end?
OCGN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Ocugen, Inc.'s official SEC filings (10-K and 10-Q), covering 12 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.